US 12,280,067 B2
Formulations of creatine and cyclodextrin exhibiting improved bioavailability
Michael S Tempesta, El Granada, CA (US); and F. Joseph Daugherty, Omaha, NE (US)
Assigned to Phenolics, LLC, Omaha, NE (US)
Filed by Michael S Tempesta, El Granada, CA (US); and F. Joseph Daugherty, Omaha, NE (US)
Filed on Apr. 23, 2019, as Appl. No. 16/392,475.
Prior Publication US 2022/0211729 A1, Jul. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/664 (2006.01); A61K 9/00 (2006.01); A61K 9/50 (2006.01); A61K 31/205 (2006.01); A61K 47/10 (2017.01); A61K 47/40 (2006.01)
CPC A61K 31/664 (2013.01) [A61K 9/0053 (2013.01); A61K 9/5026 (2013.01); A61K 31/205 (2013.01); A61K 47/10 (2013.01); A61K 47/40 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A coated creatine supplement manufactured by a process comprising the steps of:
co-granulating disodium phosphocreatine, and gamma cyclodextrin; to form a granular composition having an average particle size of from 150 to 850 microns; and
coating the granular composition with methacrylate copolymers to produce the coated creatine supplement;
wherein the coated creatine supplement comprises:
75% to 95% by weight disodium phosphocreatine;
2% to 10% by weight gamma cyclodextrin; and
1-10% by weight methacrylate copolymer coating.